Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04222621
Other study ID # REPRESENT
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 2008
Est. completion date December 2023

Study information

Verified date January 2020
Source West China Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To improve the health of women and children under the background of Healthy China 2030, the investigators developed REPRESENT by establishing a pregnancy registry in Xiamen, a sub-provincial city of over four million residents in east China, based on the Maternal and Child Health Management Platform, and then linking to three other platforms, i.e. Residents Healthcare Management Platform, Primary Healthcare Management Platform, and Electronic Healthcare Records (EHR) Platform, which had been developed since 2006. The registry documented information and events about pregnant women from registration at their first trimester to postpartum, and includes the childhood follow up records. The registry not only enables longitudinal follow up of pregnant women and their offspring, but also expands the scope of database from pre-pregnancy exposures to long-term outcomes by data linkage.

During the past 11 years (January 2008 to March 2019), the REPRESENT has accumulated data concerning more than 700 thousands pregnancies. The data volume is substantial with over 800 variables being documented, and most variables are designed as structured fields. The disease categories and codes are standardized according to the International Classification of Diseases 10th Revision (ICD-10). The whole process of data access, data extraction, data processing and data analysis was conducted through an internal-only accessible server at Xiamen Health and Medical Big Data Center. All investigators cannot access sensitive information, are required to sign data confidentiality agreement and should obtain approval by the Xiamen Health and Medical Big Data Center and the Chinese Evidence-based Medicine Center.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 761194
Est. completion date December 2023
Est. primary completion date March 2019
Accepts healthy volunteers No
Gender Female
Age group 14 Years to 65 Years
Eligibility Inclusion Criteria:

- Pregnant women who registered at the Maternal and Child Health Management Platform in Xiamen.

Exclusion Criteria:

- None.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pregnant women without intervention
Pregnant women with those exposures of interest determined in specific research based on the registry

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
West China Hospital Xiamen Health and Medical Big Data Center, Xiamen Health Commission

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of pre-eclampsia Maternal systolic blood pressure = 140 mmHg and (or) diastolic pressure = 90 mmHg, accompanied by any one of the following: urinary protein = 0.3g/24 h, or the ratio of urinary protein and creatinine = 0.3, or random urine protein = (+) if quantitative urine protein is not available; no proteinuria but with any damages of heart, lung, liver, kidney and other important organs, or with abnormal changes of blood system, digestive system and nervous system, or placenta fetus involvement, etc. Up to 42 weeks
Primary Incidence of eclampsia Tonic-clonic seizures (convulsions) in preeclampsia patients, including convulsions and coma, not due to pre-existing or organic brain disorders. Up to 42 weeks
Primary Incidence of gestational diabetes By oral glucose tolerance test between 24 and 28 gestational weeks (fasting glucose =5.1 mmol/L, 1-h glucose =10.0 mmol/L, 2-h glucose =8.5 mmol/L; one abnormal result sufficient). Up to 32 weeks
Primary Incidence of ruptured uterus Rupture of maternal uterus confirmed by laparotomy. Up to 42 weeks
Primary Incidence of postpartum hemorrhage Postpartum bleeding volume =500 mL. Within 24h after delivery
Primary Incidence of maternal death Maternal death Up to 52 weeks
Primary Incidence of birth defects Birth defects such as anencephaly, spina bifida, encephalocele, hydrocephalus, cleft palate, cleft lip, microtia, esophageal atresia or stenosis, anorectal, hypospadias, ectropion of bladder, talipes equinovarus, polydactylism, ankylodactylia, congenital diaphragmatic hernia, umbilical cord prolapse, gastroschisis, conjoined twins, down syndrome, congenital heart disease, or other birth defects. Up to 7 years
Primary Incidence of preterm birth Delivery before 37th gestational weeks. Up to 37 weeks
Primary Incidence of neonatal birth weight Neonatal birth weight measured after birth. Up to 42 weeks
Primary Incidence of neonatal death Neonatal death Within 28 days after delivery
Primary Incidence of stillbirth Fetus death at or after 20-28 weeks of gestation. Up to 42 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03955263 - Malaria In Pregnancy in Central India
Not yet recruiting NCT04457947 - Exploring Aromatherapy Intervention in Acute Care
Active, not recruiting NCT01397318 - Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight N/A
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
Not yet recruiting NCT00931099 - Fetal Outcome of Sleep Disordered Breathing During Pregnancy N/A
Recruiting NCT00751569 - microRNA Profile in Umbilical Cord Blood NK Cells N/A
Completed NCT06111716 - Mindfulness in Childbirth Preparation Education Process N/A
Completed NCT05729191 - Evaluation of the Acceptance of the Anti-COVID-19 Vaccine Offer Among Pregnant Women
Completed NCT01687634 - Home Visiting for Low Income, Pregnant Women N/A
Recruiting NCT05446571 - Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir Phase 3
Not yet recruiting NCT03651934 - Verification of Correlation Between Genetic Testing of Nutritional Metabolism and Clinical Biochemical Indicators N/A
Active, not recruiting NCT06422130 - Ningbo Maternity-Child Linked Database Study
Completed NCT02904473 - Goals for Reaching Optimum Wellness (GROWell) N/A
Completed NCT03538106 - Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes
Recruiting NCT01246765 - National Pregnancy Registry for Psychiatric Medications
Completed NCT00553228 - Pertussis Maternal Immunization Study Phase 2/Phase 3
Recruiting NCT05916534 - We Care About Brooklyn - A Digital Behavioral Intervention to Optimize Engagement in Maternal Healthcare N/A
Completed NCT04264910 - CALM Pregnancy: Feasibility of Calm for Pregnant Women N/A
Completed NCT04494581 - GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
Recruiting NCT05349279 - Qatar PREgnancy Covid-19 OUtcome Study